Neurology® Podcast

1) Multiple sclerosis: A meta-analytic approach 2) Ultrasound of peripheral nerves (Part 2). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Maria Pia Sormani about her paper on multiple sclerosis: A meta-analytic approach. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Terson syndrome. In the next part of the podcast Dr. Mary Lussier interviews Dr. Michael Cartwright for part two on peripheral nerve ultrasound for our Lesson of the Week. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Sormani, Keegan, Fugate, and Cartwright.

1) Mild cognitive decline 2) Ultrasound of peripheral nerves (Part 1). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Susan Landau about her paper on mild cognitive decline. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Doi's sign. In the next part of the podcast Dr. Mary Lussier interviews Dr. Michael Cartwright for part one on peripheral nerve ultrasound for our Lesson of the Week. The participants had nothing to disclose except Drs. Landau, Fugate, and Cartwright. Dr. Landau receives research support from the NIH (U01 AG024904 [Research specialist]).Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Cartwright receives research support from the NIH (1K23 N5062892-01A1) and has received speaker honoraria from AANEM and ASN annual meetings.

In this special podcast for the Neurology Journal, Dr. Ted M. Burns plays a dozen of the many interesting audio clips from Neurology Podcasts of the 2009-2010 academic year.

1) Diagnosis of acute ischemic stroke and 2) evidence-based medicine (Part 3). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Peter Schellinger about his paper on diagnosis of acute ischemic stroke. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about digiti quinti sign. In the next part of the podcast Dr. Michael Benatar interviews Dr. Mark Conaway for part three on evidence-based medicine probability, odds, and odds ratio for our Lesson of the Week. The participants had nothing to disclose except Drs. Kissela, Schellinger and Fugate. Dr. Kissela served on the scientific advisory board for Allergan, Inc in 2009; served as a consultant for Allergan for 2-day meeting in 2009; received honoraria from CME program and unrestricted educational grants; received research support from the NIH [R01 NS 30678], [N01 NS 081588], [1Ul1 RR026314] and received compensation for reviewing records for several medical/legal cases regarding stroke.Dr. Schellinger has served/serves on scientific advisory boards for Boehringer Ingelheim, ImaRx Therapeutics, Photothera, Cerevast, and CoAxia, Inc.; has served/serves on speakers' bureaus for and received funding for travel and speaker honoraria from Boehringer Ingelheim, Sanofi, ImaRx Therapeutics, Photothera, Cerevast, CoAxia, Inc., Solvay Pharmaceuticals, Inc., and GlaxoSmithKline; serves on editorial boards of Stroke and European Neurology; receives royalties from the publication of NeuroIntensiv (Springer, 2008) and received royalties from the publication of Stroke MRI (Steinkopff, 2004); has served as a consultant for CoAxia, Inc., Photothera, Cerevast, ImaRx, and Boehringer Ingelheim; and has provided expert testimony, affidavits, and acted as a witness or consultant in legal proceedings.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Depressive symptoms and risk of dementia and 2) Early history of the AAN. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Geldmacher interviews Dr. Jane Saczynski about her paper on depressive symptoms and risk of dementia. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about wrong way eyes. In the next part of the podcast Dr. Ted Burns interviews Dr. Robert Joynt on the early history of the AAN for our Lesson of the Week. The participants had nothing to disclose except Drs. Fugate, Burns and Joynt. Dr. Geldmacher serves on editorial board of Brain Injury, has received speaker honoraria from Danville Regional Medical Center, Georgetown Medical School, University of Rochester, Cleveland Clinic, Kaiser Permanante and Academy for Healthcare Education, receives research support from Elan Corporation [PI], Eisai Inc. [PI], Medivation, Inc. [PI], Janssen [PI] and Novartis [PI].Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).Dr. Joynt receives a stipend as Newsletter Editor for Neurology® and royalties from Archives of Neurology for published work.

1) Imaging in acute stroke and 2) conflicts of interest: A personal perspective. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Yves Samson about his paper on diffusion-weighted MR imaging in acute stroke. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about posterior vermal split syndrome. In the next part of the podcast Dr. Matthew Wong interviews Dr. Joseph Martin for our Lesson of the Week about his paper on the pervasive influence of conflicts of interest. The participants had nothing to disclose except Drs. Kissela, Samson and Martin. Dr. Kissela served on the scientific advisory board for Allergan, Inc in 2009; served as a consultant for Allergan for 2-day meeting in 2009; received honoraria from CME program and unrestricted educational grants; received research support from the NIH [R01 NS 30678], [N01 NS 081588], [1Ul1 RR026314] and received compensation for reviewing records for several medical/legal cases regarding stroke. Dr. Samson is co-inventor of Neurinfarct software (Patent WO 2008/000973, issued 2008) currently owned by Intelligence in Medical Technologies, Paris; and holds stock in Intelligence in Medical Technologies. Dr. Martin has been on the Board of Directors at Baxter International for 8 years. For a short narrative describing this activity in greater detail, and the effect it had on Dr. Martin's activities, please see appendix e-1 at www.neurology.org

1) Restless legs syndrome and 2) evidence-based medicine (part 2). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Aman Savani interviews Dr. Diego Garcia-Borreguero about his paper on restless legs syndrome. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about fatal gastroenteritis. In the next part of the podcast Dr. Michael Benatar interviews Dr. Mark Conaway for part two on evidence-based medicine relative risk, relative risk reduction, absolute risk reduction, and NNT for our Lesson of the Week. You may also want to check out the other two-part series on evidence-based medicine where Dr. Michael Benatar interviewed Dr. Gary Gronseth for our March 30 and April 6 Lesson of the Week. The participants had nothing to disclose except Dr. Garcia-Borreguero. Dr. Garcia-Borreguero has served on scientific advisory boards for and received speaker honoraria from Boehringer Ingelheim, GlaxoSmithKline, UCB, Pfizer Inc, XenoPort, Inc., sanofi-aventis, Jazz Pharmaceuticals, and Merck & Co., Inc.

1) Embouchure dystonia and 2) progressive myoclonic encephalopathies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Robert Pascuzzi interviews Dr. Bernhard Haslinger about his paper on embouchure dystonia. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the corneal reflex in stroke. In the next part of the podcast Dr. Alberto Espay interviews Dr. Berge Minassian for part 2 on progressive myoclonic encephalopathies for our Lesson of the Week. The participants had nothing to disclose except Drs. Haslinger, Pascuzzi and Espay. Dr. Haslinger serves on a scientific board for Merz Pharmaceuticals, LLC; has received funding from travel from Ipsen, Merz Pharmaceuticals, LLC, and Medtronic, Inc.; has received speaker honoraria from Novartis, GlaxoSmithKline, Desitin Pharmaceuticals, GmbH, Ipsen, and Allergan, Inc.; receives research support from Ipsen and from the German Research Foundation (DFG).Dr. Pascuzzi serves on the Board of Directors of the ABPN; serves on the Neurology RRC; served as immediate past Program Director for Neurology Residency Training at Indiana University; participates in multicenter clinical trials for a variety of neuromuscular disorders but receives no direct compensation; and gives lectures for the AAN and at multiple academic medical centers but does not received personal compensation.Dr. Espay received has personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.

1) Guillain-Barré syndrome vs. CIDP and 2) progressive myoclonic encephalopathies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Erik Ensrud interviews Dr. Pieter van Doorn about his paper on Guillain-Barré syndrome. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about Harlequin syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Berge Minassian for part 1 on progressive myoclonic encephalopathies for our Lesson of the Week. The participants had nothing to disclose except Drs. van Doorn and Espay.Dr. van Doorn receives research support from the Prinses Beatrix Fonds, the GBS-CIDP Foundation International and from Baxter biopharmaceutics.Dr. Espay received has personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.

Frontotemporal dementia and advocacy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Eneida Mioshi about her paper on frontotemporal dementia. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about atypical unilateral severe facial pain in smokers. In the next part of the podcast Dr. Ted Burns interviews Dr. Robert Griggs on advocacy for our Lesson of the Week. The participants had nothing to disclose except Drs. Mioshi, Burns and Griggs.Dr. Mioshi serves on the editorial board of Dementia and Geriatric Cognitive DisordersDr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).Dr. Griggs serves on the editorial advisory board for Current Treatment Options in Neurology and NeuroRX; has received honoraria for lectures or educational activities not funded by industry; receives research support from the NINDS T32 NS07338 [PI]; NIH 2U54 NS059065-06 [PI], R01 NS045686-05 [PI], NIH-R13 Fostering Pharma, NINDS 525326 FOR-DMD, and FDA 2-RO1FD003454-02 [Co-PI] and TaroPharma; receives funding support from MDA Fostering Pharma-Academic Partnerships in Neuromuscular Experimental Therapeutics, Muscular Dystrophy Association Experimental Therapeutics of Neuromuscular Disease and Recruitment for HYP HOP Phase III trial in the Periodic paralyses (PI); and receives royalties from the publication of the book, Cecil Textbook of Medicine, 23 Edition.